

Nathalie Kapp, MD, MPH

Education

07/2004–05/2006	Masters in Public Health, Biostatistics Boston University Boston, Massachusetts
09/1996–06/2000	Doctor of Medicine University of Utah Salt Lake City, Utah
06/1991–06/1996	Bachelor of Science Boise State University Boise, Idaho

Postdoctoral Training

07/2004–06/2006	Boston University Fellow, Clinical Research Training Program
07/2004–06/2006	Boston University Fellow, Family Planning and Clinical Research Department of Obstetrics and Gynecology
01/2003–06/2004	Dartmouth-Hitchcock Medical Center Obstetrics and Gynecology Residency
06/2000–12/2002	University of Utah Medical Center Obstetrics and Gynecology Residency

Positions and appointments

2/2016- present	Senior Advisor Ipas Chapel Hill, NC
3/2013- 2/2016	Senior Medical Officer Women's Health Clinical Development HRA Pharma, Paris
9/2006 – 2/2013	Medical Officer Reproductive Health and Research World Health Organization, Geneva
9/2006 – 9/2008	Assistant Professor of Research Department of Maternal and Child Health University of North Carolina, Chapel Hill

7/2004– 7/2006 **Clinical Instructor**
 Department of Obstetrics and Gynecology
 Boston Medical Center

Awards and Honors

2015 **First Prize in the BMA 2015 Medical Book awards** in the Obstetrics and Gynaecology category for the publication *Clinical practice handbook for safe abortion*
 Role: inception of and writing the handbook

2007 **Ortho Award for Outstanding Researcher-in-Training**
 Annual meeting, Association of Reproductive Health Professionals

2005 **Blue Ribbon: Poster Presentation**
 Simultaneous Low-Dose Mifepristone and Vaginal Misoprostol for Medical Abortion
 American College of Obstetricians and Gynecologists,
 Annual Clinical Meeting

2004 **Wyeth Pharmaceuticals New Leaders Award: Advancing a New Generation of Reproductive Health Professionals**
 Annual meeting, Association of Reproductive Health Professionals

1999 **Alpha Omega Alpha Honorary Medical Society**
 University of Utah

1999 **Olga Alexandra Logan and David Wood Memorial Scholarship, Scholastic Achievement**
 University of Utah (two separate scholarships)

1998 **Olga Alexandra Logan Scholarship, Scholastic Achievement**
 University of Utah

1997 **Frenkel Scholarship, Scholastic Achievement**
 University of Utah

1996 **BS, Summa Cum Laude, College of Arts and Sciences**
 Boise State University, Idaho

Licensure

2004-present **State of Massachusetts Active Medical License**

Memberships and Committee Assignments in Professional Societies

2006 - present Society for Family Planning, Fellow

2004 – present National Abortion Federation Member

2004 – present	Association of Reproductive Health Professionals, Member
2000 – 2007	American College of Obstetricians and Gynecologists, Junior Fellow
1996– 2000	American Medical Women’s Association, Member

Major Committee Assignments and Consultations

2015	Advisor Royal College of Obstetrics and Gynaecology
2015	Consultant Ipas
2015-2016	Advisor BPAS Clinical Advisory Group
2014	Advisor SFP Research Fund priority setting group
2011-present	Grant Reviewer Fellowship in Family Planning
2011- 2015	Advisor Technical Advisory Group for Pericoital Oral Contraception, Gynuity
2009- present	Member International Consortium for Emergency Contraception Advisory Committee
2007– 2008	Member Ethics Review Committee, World Health Organization
2006–present	Peer Reviewer <i>Cochrane Database of Systematic Reviews</i> <i>Contraception</i> <i>The American Journal of Obstetrics & Gynecology</i> <i>International Journal of Obstetrics and Gynecology</i> <i>Reproductive Health Matters</i> <i>Fertility and Sterility</i> <i>Global Public Health</i> <i>European Journal of Contraception and Reproductive Health Care</i> <i>The Medscape Journal of Medicine</i>
2005–2006	Member, Medical Board NARAL Massachusetts
2001–2002	Reproductive Endocrinology Fellowship Development Committee University of Utah Medical Center
1999–2000	Admissions Committee University of Utah Medical School

Peer-reviewed publications

1. Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. *Contraception*. Sep, 2016;94(3):262-274.
2. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception*. Sep, 2016;94(3):226-252.
3. Dragoman MV, Grossman D, Kapp N, Huong NM, Habib N, Dung DL, Tamang A. Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days gestation with mifepristone and misoprostol: study protocol for a randomised, controlled trial. *Reproductive Health*, 2016; 13:132.
4. Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, Brache V. A prospective, open-label, multicentre study to assess the pharmacodynamics and safety of repeated use of 30mg ulipristal acetate. *Contraception*, 2016; 93: 310-16.
5. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception*, 2015.
6. Brache V, Cochon L, Duijkers IJ, Levy DP, Kapp N, Monteil C, Abitbol JL, Klipping C. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Human Reproduction*, 2015; 30(12) : 2785-93.
7. Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. *Contraception*, 2015, online 19 May.
8. Kapp N, Abitbol JL, Mathe H, Scherrer B, Guillard H, Gainer E, Ulmann A. Effect of weight and BMI on the efficacy of levonorgestrel emergency contraception. *Contraception*, 2015;91(2):97-104.
9. Sonalkar S, Kapp N. Intrauterine device insertion in the postpartum period: A systematic review. *European Journal of Contraception and Reproductive Health Care*, 2015;20(1):4-18.
10. Levy DP, Jager M, Kapp N, Abitbol JL. Ulipristal acetate for emergency contraception: post-marketing experience after use by more than 1 million women. *Contraception*, 2014;89(5):431-3.
11. Westley E, Kapp N. A review of global access to emergency contraception. *International Journal of Gynecology and Obstetrics*, 2013; 123 (1):4-6.
12. Kapp N, Glasier A. WHO technical and policy guidance emphasizes the health systems' responsibility to provide safe abortion services. *Contraception*, 2013; 87(5):511-2.

13. Tang J, Kapp N, Dragoman M, Souza JP. WHO Recommendations for misoprostol for obstetric and gynaecologic indications. *International Journal of Obstetrics and Gynecology*, 2013; 121(2):186-9.
14. Kapp N, Whyte P, Tang J, Jackson E, Brahmi D. A review of evidence for safe abortion care. *Contraception*, 2013 Sep;88(3):350-63.
15. Rodriguez MI, Curtis KM, Gaffield ML, Jackson E, Kapp N. Advance supply of emergency contraception: a systematic review. *Contraception*, 2013;87(5):590-601.
16. Kapp N, Gaffield ML. Initiation of progestogen-only injectables on different days of the menstrual cycle and its effect on contraceptive effectiveness and compliance. *Contraception*, 2013; 87(5):576-82.
17. Salcedo J, Rodriguez M, Curtis K, Kapp N. When can a woman resume or initiate Contraception after taking Emergency contraceptive pills? *Contraception*, 2013; 87(5):602-4.
18. Renner R, Brahmi D, Kapp N. Who can safely and effectively provide abortion services ? *BJOG*, 2013;120(1):23-31.
19. Maria Isabel Rodriguez, Armando Seuc, Nathalie Kapp, Helena von Hertzen, Nguyen Thi My Huong, Daniel Wojdyla, Suneeta Mittal, Karine Arustamyan, Rashmi Shah and the World Health Organization Research Group on Post-Ovulatory Methods of Fertility Regulation. Acceptability of misoprostol-only medical abortion compared with vacuum aspiration: an international, multicentre trial. *BJOG* 2012;119(7):817-23.
20. Low N, Mueller M, Van Vliet HAAM, Kapp N. Perioperative antibiotics to prevent infection after first trimester abortion. *Cochrane Database of Systematic Reviews* 2012,Mar 14;3:CD005217.
21. Steenland M, Tepper N, Curtis K, Kapp N. Intrauterine contraceptive insertion post-abortion: a systematic review. *Contraception*, 2011;84(5):447-64.
22. Rodriguez M, Edelman A, Kapp N. Postpartum sterilization with the titanium clip: a systematic review. *Obstetrics & Gynecology*, 2011; 118(1):143-147.
23. Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. *Contraception*, 2011;84(1): 35-9.
24. Borgatta L, Kapp N. Medical abortion in the second trimester: Society for Family Planning Guidelines. *Contraception*, 2011, 84(1): 4-18.
25. Betstadt SJ, Turok DK, Kapp N, Feng KT, Borgatta L. Intrauterine device insertion after medical abortion. *Contraception*, 2011; 83 (6): 517-521.
26. Jackson E, Kapp N. Pain control in first and second trimester medical termination of pregnancy: A systematic review. *Contraception*, 2011; 83(2): 116-26.

27. Kulier R, Kapp N. The use of pre-procedure ultrasound for first and second- trimester abortion. *Contraception*, 2011; 83(1):30-3.
28. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. *Cochrane Database of Systematic Reviews* 2011, Issue 1. Art. No.: CD005216. DOI: 10.1002/14651858.CD005216.pub2.
29. Kulier R, Kapp N, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. *Cochrane Database of Systematic Reviews* 2011, Issue 11. Art. No.: CD002855. DOI: 10.1002/14651858.CD002855.pub4.
30. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion; Centers for Disease Control and Prevention (CDC), Farr S, Folger SG, Paulen M, Tepper N, Whiteman M, Zapata L, Culwell K, Kapp N, Cansino C. U S. Medical Eligibility Criteria for Contraceptive Use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. *MMWR Recomm Rep*. 2010 Jun 18;59(RR-4):1-86.
31. Kapp N, Curtis KM. Combined oral contraceptive use among breastfeeding women: a systematic review. *Contraception*, 2010; 82 (1):10-16.
32. Kapp N, Curtis KM, Nanda K. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception*, 2010; 82(1):17-37.
33. Carr Ellis S, Kapp N, Vragovic O, Borgatta L. Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion. *Contraception*, 2010;81(5):441-5.
34. Kapp N, Lohr PA., Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion. *Cochrane Database of Systematic Reviews* 2010 Feb 17; 2:CD007207.
35. Curtis, KM; Nanda, K; Kapp, N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. *AIDS*, 2009; 23(1):S55-S67.
36. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: A systematic review. *Contraception*, 2009; 80(4): 327-36.
37. Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: A systematic review. *Contraception*, 2009; 80(4): 381-6.
38. Kapp N, Curtis KM. Hormonal contraceptive use among women with liver tumors: A systematic review. *Contraception*, 2009; 80(4): 387-90.
39. Gaffield ME, Kapp N, Ravi A. Use of combined oral contraceptives post-abortion: A systematic review. *Contraception*, 2009; 80(4): 355-62.
40. Gaffield ME, Kapp N, Curtis KM. Combined oral contraceptive and intrauterine device use among women with gestational trophoblastic disease: A systematic review. *Contraception*, 2009; 80(4): 363-71.

41. Schwingl PJ, Meirik O, Kapp N, Farley TMM. Prostate cancer and vasectomy: a hospital-based case-control study in China, Nepal and the Republic of Korea. *Contraception*, 2009; 79(5): 363-368.
42. Kapp N. A review of mifepristone combined with misoprostol for second trimester induction abortion. *Female Patient*. October, 2008.
43. Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N. Mifepristone in midtrimester medical abortion: A randomized controlled trial. *Obstetrics & Gynecology*, 2007; 110: 1304-1310
44. Kapp N, Curtis KM, Borgatta L. Study design to evaluate the safety and effectiveness of hormonal contraception for women. *Clinical Obstetrics and Gynecology*, 2007; 50(4): 850-867.
45. Kapp N, Todd CS, Yadgarova KT, Alibayeva G, Nazarova D, Loza O, Guldjahan SB. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2 analogue for second trimester induction termination in Uzbekistan. *Contraception*, 2007; 76(6): 461-466.
46. Prairie BA, Lauria M, Kapp N, MacKenzie T, Baker E, George KA. Mifepristone versus laminaria: A randomized controlled trial of cervical ripening in midtrimester termination. *Contraception*, 2007;76(5):383-8.
47. Jeong Y, Borgatta L, Kapp N, Peter I, Bianchi DW, Johnson KL. Short-term clearance of cell-free nucleic acids following first trimester termination of pregnancy. *Fertility and Sterility*, 2007; 96 (3): 212-8.
48. Moreno N, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to mifepristone for medical abortion. *International Journal of Gynecology and Obstetrics*, 2007 96(3): 212-8.
49. Kapp N, Borgatta L, Carr Ellis S, Stubblefield P. Simultaneous very low-dose mifepristone and vaginal misoprostol. *Contraception*, 2006;73:525-527.

Book chapters

Kapp N, von Hertzen H. Medical methods to induce abortion in the second trimester. M. Paul, Ed, *Management of unintended and abnormal pregnancy*, Chapter 12, Wiley-Blackwell, West Sussex, 2009.

Stubblefield PG, Carr Ellis S, Kapp N: *Family Planning*. J. Berek, Ed, *Novak's Gynecology*, 14th Edition, Chapter 10, Lippincott, Williams and Wilkins, Philadelphia, 2006.